September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease

Akshat Jain/Loma Linda University Health

Mar 12, 2026, 20:19

Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease

Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Patients with Sickle Cell Disease suffer from severe pain!

We know that Pain medications are mainstay in management of these patients but can this be used as a marker to study severity of Sickle Cell Disease as a Validated marker for outcome assement, clinical trials and therapuetic efficacy?

Pain is subjective, OPM is objective.

Honored to share that our latest work to validate Oral Pain Medication (OPM) as a truly global marker for sickle cell disease has just been published in EJHaem (Wiley).

In this truly global study across 5 continents from 11 countries, we examine real-world patterns of care and the ongoing burden of SCD complications across the age spectrum, highlighting how organ damage, acute events, and healthcare utilization remain substantial despite available therapies.

These data underscore the persistent unmet need in SCD and the importance of expanding access to disease-modifying and curative options, while optimizing supportive care for patients and families.

Grateful to my co-authors, collaborators, and patients who made this work possible.”

Title: Global Burden of Sickle Cell Disease: Adequacy of Pain Control as Evidenced by Frequency of Oral Pain Medication Use, Health Outcomes, and Emotional Well-Being Across Diverse Populations

Authors: Akshat Jain, Lisa Roberts, Safiye Sahin

Read the Full Article on eJHaem

Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease